# A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel

> **NCT01949324** · PHASE2 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 67 (actual)

## Conditions studied

- Macular Telangiectasia Type 2

## Interventions

- **BIOLOGICAL:** Ciliary neurotrophic factor (CNTF)
- **PROCEDURE:** Sham procedure
- **DEVICE:** NT-501 Implant
- **PROCEDURE:** NT-501 Implant procedure

## Key facts

- **NCT ID:** NCT01949324
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2017-04-14
- **Final completion:** 2017-05-22
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2018-09-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01949324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01949324, "A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01949324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*